Exercise Tips While on Zepbound (Tirzepatide)

Zepbound and Mounjaro are the same drug. The active ingredient is tirzepatide in both cases. What differs is the indication: Mounjaro is prescribed for type 2 diabetes, Zepbound for weight management. In the UK, the brand distinction doesn't exist at all. Tirzepatide is sold only as Mounjaro there, whether you're taking it for blood sugar or body weight.

If you're on Zepbound, you're using tirzepatide specifically for weight loss. That context shapes which trial data is most relevant to you, and which exercise questions matter most. The exercise tips for Mounjaro post covers the diabetes-specific context in detail, including the dual GIP/GLP-1 mechanism, the SURMOUNT-1 body composition data, and SURPASS-3 muscle quality findings. Read that for the foundational science. This post focuses on what's different or particularly relevant for Zepbound users.

For the broader case for exercising on any GLP-1 medication, why exercise matters on GLP-1s covers that separately.

---

What SURMOUNT-5 changes

In May 2025, the New England Journal of Medicine published SURMOUNT-5, the first head-to-head randomised trial comparing tirzepatide directly against semaglutide for weight management. 751 participants without type 2 diabetes were randomised to the maximum tolerated dose of tirzepatide (10mg or 15mg) or semaglutide (1.7mg or 2.4mg) for 72 weeks.

The results were more decisive than most researchers expected.

Tirzepatide produced an average weight loss of 20.2% of body weight. Semaglutide produced 13.7%. In absolute terms, that's 22.8kg versus 15.0kg. Nearly half (48.4%) of tirzepatide participants achieved 20% or more weight loss, compared with 27.3% on semaglutide. A third (32%) achieved 25% or more weight loss, versus 16% on semaglutide.

The tolerability finding is worth noting separately. Gastrointestinal side effects caused 5.6% of semaglutide participants to discontinue the trial, compared with 2.7% on tirzepatide. Tirzepatide was better tolerated despite producing substantially greater weight loss.

For exercise, both findings matter. More weight coming off means body composition management becomes more important. Fewer nausea-disrupted training days means more uninterrupted weeks across a 72-week programme. The two effects work together.

---

The sleep apnoea angle

In December 2024, the FDA approved Zepbound for a second indication: moderate-to-severe obstructive sleep apnoea (OSA) in adults with obesity. It's the first drug approved for OSA. The evidence came from the SURMOUNT-OSA trial.

The primary measure in OSA trials is the apnoea-hypopnoea index (AHI), which counts breathing disruptions per hour of sleep. In SURMOUNT-OSA, tirzepatide reduced the AHI by around 25-29 events per hour from baseline, compared with roughly 5-6 events per hour on placebo. Between 42% and 50% of tirzepatide participants achieved full remission or mild non-symptomatic OSA, compared with about 15% on placebo.

This matters for exercise in a practical way. Poor sleep directly impairs workout recovery, reduces motivation to be active, and makes high-intensity exercise harder to sustain. OSA in particular fragments the deep sleep stages where physical repair happens. If you're on Zepbound and have OSA, the improvement in sleep quality is likely contributing to exercise capacity in ways that don't show up cleanly in a training log.

The loop looks like this: better sleep supports better recovery, which supports more regular exercise, which supports better weight maintenance. Zepbound's OSA approval is relevant to that chain even if OSA isn't your primary reason for taking it.

---

Exercise as your exit strategy: what SURMOUNT-4 shows

SURMOUNT-4 is the most practically important trial for anyone thinking about long-term use. Participants spent 36 weeks on tirzepatide at maximum tolerated dose (10mg or 15mg), achieving substantial weight loss. They were then randomised to either continue tirzepatide or switch to placebo for a further 52 weeks.

Those who continued tirzepatide lost a further 5.5% of body weight over that period. Those who switched to placebo regained 14.0%. At week 88, only 16.6% of the placebo group had maintained 80% or more of their original weight loss. In the tirzepatide group, 89.5% maintained that threshold.

The lesson isn't that the drug must be taken indefinitely. Many people stop for reasons that are practical rather than medical: cost, supply, personal choice, access changes. The lesson is that without something replacing the appetite suppression effect, the weight returns.

Exercise builds the physiological and habitual infrastructure that can partially fill that role. Preserved lean mass raises resting metabolic rate, which changes the calorie balance equation even when the drug is gone. Established movement habits change daily behaviour in ways that persist longer than the medication's half-life. The habit-building research suggests that exercise habits formed during treatment are the strongest predictor of what happens after.

The frame that fits the data: build the exercise habit during treatment, while the appetite suppression makes the calorie side easier to manage, so it's in place when that suppression eventually disappears.

---

The dose schedule and what to expect from exercise at each step

Zepbound follows a six-step escalation, with increments of 2.5mg every four weeks at minimum. That's six adjustment windows over 20-plus weeks before reaching maximum dose. Wegovy reaches its target in five steps over 16 weeks. Every step up brings a fresh period of heightened GI symptoms and, for some people, reduced energy.

2.5mg (weeks 1-4)

The starting dose is almost entirely about tolerability. Appetite suppression at this level is minimal. Most people feel close to normal. This is the window to establish the exercise habit before escalation makes it harder. Start resistance training now. Build the walking routine. Don't waste this period waiting for things to get more challenging.

5mg (weeks 5-8)

Appetite suppression becomes noticeable. Nausea appears for many people in the days following each injection. Vomiting was reported by 13% of participants in the SURMOUNT trials across the escalation period. Keep sessions shorter in the first two to three days post-injection. Prioritise walking on harder days. This is about protecting the habit, not optimising performance.

7.5mg (weeks 9-12)

A transition dose that's rarely used as a long-term maintenance level, but still represents a full adjustment window. Weight loss is often accelerating noticeably at this stage. That acceleration is the signal that protein intake needs deliberate attention. When weight is coming off quickly, so is lean mass if you're not working to preserve it.

10mg (weeks 13-16)

One of the two recommended maintenance doses. For many people, side effects have started to settle into a predictable pattern by this point. The exercise approach from the earlier doses still applies: harder sessions later in the injection cycle, more flexibility near the injection day.

12.5mg (weeks 17-20)

Another transition step. Some people stay here rather than escalating further, especially if 10mg is producing good results with tolerable side effects. A fresh adjustment window is still possible even if the earlier steps felt manageable.

15mg (week 21+)

Maximum maintenance dose. Clinical trial data shows nausea in up to 29% of participants and fatigue in 5-7% at maintenance doses. Individual responses vary considerably. Some people tolerate 15mg without significant difficulty. Others find it more demanding than any earlier step.

Worth knowing: you don't have to reach 15mg. The recommended maintenance doses in the Zepbound prescribing guidance are 10mg and 15mg. If 10mg is working and the side effect profile is manageable, staying there is a reasonable choice. The goal is the most effective dose you can sustain, not the highest dose on the schedule.

---

What this means practically for exercise

Muscle preservation matters more here than on semaglutide

Because Zepbound produces greater total weight loss than semaglutide, the absolute amount of lean mass at risk is larger, even if the proportion (roughly 25% of total weight lost in the SURMOUNT-1 body composition substudy) is more favourable than semaglutide's 45%. In SURMOUNT-1, participants lost an average of 10.9% of lean mass over 72 weeks, alongside a 33.9% reduction in fat mass and a 40.1% reduction in visceral fat.

Resistance training is the tool most supported by evidence for keeping that lean mass proportion as low as possible. Two to three sessions per week of compound movements, squats, lunges, push-ups, rows, glute bridges, covering all major muscle groups, gives the body the mechanical signal it needs to preserve muscle during a steep calorie deficit. Sessions don't need to be long. Twenty to thirty minutes is enough.

For specific workout structures, the best workouts on semaglutide post covers a beginner weekly plan in detail. The principles apply directly to tirzepatide.

The tolerability advantage means more consistent weeks

The SURMOUNT-5 finding that tirzepatide had roughly half the GI discontinuation rate of semaglutide (2.7% vs 5.6%) suggests that the side effect burden during treatment is meaningfully more manageable than semaglutide for many people. In practice, that translates to fewer weeks where nausea or fatigue makes exercise genuinely hard. That's a real advantage for building a consistent training habit over a 20-plus week escalation.

It doesn't mean GI symptoms are absent. Nausea up to 29% and vomiting at 13% are still material numbers. But compared to semaglutide's profile at equivalent doses, tirzepatide tends to disrupt the exercise schedule less.

Walking remains the most reliable foundation

Walking requires the least energy of any structured aerobic activity, can be shortened mid-session if nausea arrives, and can be split across the day without losing its cardiovascular benefit. On the harder post-injection days, a 20-minute walk is not a fallback. It's the plan.

Use the walking calculator for personalised distance and calorie estimates based on your weight and pace, or the steps goal calculator to set a daily target that builds gradually.

Protein needs active attention throughout

The Obesity Medicine Association recommends 1.2-1.6g of protein per kilogram of body weight daily during pharmacologic weight loss, up to 2g/kg if you're doing regular resistance training. For a 75kg person, that's 90-150g daily.

Appetite suppression on tirzepatide is substantial and sustained. Protein intake tends to fall as a collateral consequence of eating less overall. The practical fix is to eat protein first at every meal, before the small amount of food you can comfortably manage has already filled you up. Thirty to fifty grams per meal across three meals covers most people's needs.

---

How Motion helps

Staying active across six dose escalations, fluctuating side effect days, and months of a rapidly changing body is a consistency challenge more than anything else. The weeks where everything feels manageable don't require much support. The weeks where a new dose arrives and energy crashes are what determine whether the exercise habit survives.

Motion's adaptive goals adjust based on a 12-week rolling average of your actual activity. When an escalation week disrupts output, your targets recalibrate. You're not facing an impossible number on the other side of it. When a good week pushes you further than usual, the goals don't permanently spike upward in response.

The effort-based scoring means a 20-minute walk on a rough post-injection day registers as genuine progress toward your personal target. You're measured against yourself, not against what you were doing three doses ago. On the days where half your usual effort is all you can manage, that half still counts.

Activity Battles and Fit Bingo keep engagement across the full escalation period without requiring you to be at full capacity. The Motmot virtual pet adds a gentle daily pull to keep moving even on weeks where performance metrics aren't the priority. For help choosing an app for the full course of GLP-1 treatment, this guide covers what to look for.

---

Keep the bar low, raise it when you can

Zepbound produces the strongest weight loss results of any approved medication in head-to-head data. SURMOUNT-5 made that clear. The exercise job during treatment is to ensure that as much of that weight as possible comes from fat rather than muscle, and to build the habits that hold things together if treatment ever stops.

Resistance training two to three times per week. Daily walking. Protein at every meal. Lower the bar at every dose step, raise it when things settle. Repeat across the full escalation period.

The medication handles the appetite side. Exercise handles the rest.

Try Motion free →